Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Treasury Shares (2016 - 2020)

Outlook Therapeutics (OTLK) has disclosed Treasury Shares for 6 consecutive years, with $2470.0 as the latest value for Q2 2020.

  • On a quarterly basis, Treasury Shares fell 84.69% to $2470.0 in Q2 2020 year-over-year; TTM through Jun 2020 was $2470.0, a 84.69% decrease, with the full-year FY2019 number at $2470.0, down 84.69% from a year prior.
  • Treasury Shares was $2470.0 for Q2 2020 at Outlook Therapeutics, roughly flat from $2470.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.2 million in Q1 2017 to a low of $2470.0 in Q3 2019.
  • A 5-year average of $350421.4 and a median of $140023.0 in 2018 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: rose 12.62% in 2017, then tumbled 91.86% in 2018.
  • Outlook Therapeutics' Treasury Shares stood at $243774.0 in 2016, then crashed by 32.75% to $163934.0 in 2017, then decreased by 21.25% to $129095.0 in 2018, then tumbled by 98.09% to $2470.0 in 2019, then changed by 0.0% to $2470.0 in 2020.
  • Per Business Quant, the three most recent readings for OTLK's Treasury Shares are $2470.0 (Q2 2020), $2470.0 (Q3 2019), and $16131.0 (Q2 2019).